Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity

Abstract

Advanced prostate cancer initially responds to hormonal treatment, but ultimately becomes resistant and requires more potent therapies. One mechanism of resistance observed in around 10–20% of these patients is lineage plasticity, which manifests in a partial or complete small cell or neuroendocrine prostate cancer (NEPC) phenotype. Here, we investigate the role of the mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complex in NEPC. Using large patient datasets, patient-derived organoids and cancer cell lines, we identify mSWI/SNF subunits that are deregulated in NEPC and demonstrate that SMARCA4 (BRG1) overexpression is associated with aggressive disease. We also show that SWI/SNF complexes interact with different lineage-specific factors in NEPC compared to prostate adenocarcinoma. These data point to a role for mSWI/SNF complexes in therapy-related lineage plasticity, which may also be relevant for other solid tumors.

References 102

1. 1.

   Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394-424.

   Not in our library10.3322/caac.21492 (opens in a new tab)

2. 2.

   Rawla P. Epidemiology of prostate cancer. World J. Oncol. 2019;10:63-89.

   Not in our library10.14740/wjon1191 (opens in a new tab)

3. 3.

   Robinson D, et al. Integrative clinical genomics of advanced prostate. Cancer Cell. 2015;162:454.

   Not in our library10.1016/j.cell.2015.06.053 (opens in a new tab)

4. 4.

   Beltran H, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 2016;22:298-305.

   Not in our library10.1038/nm.4045 (opens in a new tab)

5. 5.

   Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).

   Not in our library10.1073/pnas.1902651116 (opens in a new tab)

6. 6.

   Epstein JI, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am. J. Surg. Pathol. 2014;38:756-767.

   Not in our library10.1097/pas.0000000000000208 (opens in a new tab)

7. 7.

   Rickman DS, Beltran H, Demichelis F, Rubin MA. Biology and evolution of poorly differentiated neuroendocrine tumors. Nat. Med. 2017;23:1-10.

   Not in our library10.1038/nm.4341 (opens in a new tab)

8. 8.

   Aggarwal R, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 2018;36:2492-2503.

   Not in our library10.1200/jco.2017.77.6880 (opens in a new tab)

9. 9.

   Bluemn EG, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474-489.

   Not in our library10.1016/j.ccell.2017.09.003 (opens in a new tab)

10. 10.

    Metzger AL, et al. Patterns of care and outcomes in small cell carcinoma of the prostate: a national cancer database analysis. Prostate. 2019;79:1457-1461.

    Not in our library10.1002/pros.23864 (opens in a new tab)

11. 11.

    Ku SY, et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science. 2017;355:78-83.

    Not in our library10.1126/science.aah4199 (opens in a new tab)

12. 12.

    Mu P, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355:84-88.

    Not in our library10.1126/science.aah4307 (opens in a new tab)

13. 13.

    Davies AH, Beltran H, Zoubeidi A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 2018;15:271-286.

    Not in our library10.1038/nrurol.2018.22 (opens in a new tab)

14. 14.

    Kadoch C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 2013;45:592-601.

    Not in our library10.1038/ng.2628 (opens in a new tab)

15. 15.
    The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers · 2013

    No notice
16. 16.

    Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 2015;1:e1500447.

    Not in our library10.1126/sciadv.1500447 (opens in a new tab)

17. 17.

    Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 2011;21:396-420.

    Not in our library10.1038/cr.2011.32 (opens in a new tab)

18. 18.

    Ho L, et al. An embryonic stem cell chromatin remodeling complex, esBAF, is an essential component of the core pluripotency transcriptional network. Proc. Natl Acad. Sci. USA. 2009;106:5187-5191.

    Not in our library10.1073/pnas.0812888106 (opens in a new tab)

19. 19.

    Ho L, et al. esBAF facilitates pluripotency by conditioning the genome for LIF/STAT3 signalling and by regulating polycomb function. Nat. Cell Biol. 2011;13:903-913.

    Not in our library10.1038/ncb2285 (opens in a new tab)

20. 20.

    Yoo AS, Staahl BT, Chen L, Crabtree GR. MicroRNA-mediated switching of chromatin-remodelling complexes in neural development. Nature. 2009;460:642-646.

    Not in our library10.1038/nature08139 (opens in a new tab)

21. 21.

    Wu JI, et al. Regulation of dendritic development by neuron-specific chromatin remodeling complexes. Neuron. 2007;56:94-108.

    Not in our library10.1016/j.neuron.2007.08.021 (opens in a new tab)

22. 22.

    Lessard J, et al. An essential switch in subunit composition of a chromatin remodeling complex during neural development. Neuron. 2007;55:201-215.

    Not in our library10.1016/j.neuron.2007.06.019 (opens in a new tab)

23. 23.

    Versteege I, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206.

    Not in our library10.1038/28212 (opens in a new tab)

24. 24.

    Kadoch C, Crabtree GR. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell. 2013;153:71-85.

    Not in our library10.1016/j.cell.2013.02.036 (opens in a new tab)

25. 25.

    Witkowski L, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat. Genet. 2014;46:438-443.

    Not in our library10.1038/ng.2931 (opens in a new tab)

26. 26.

    Le Loarer F, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat. Genet. 2015;47:1200-1205.

    Not in our library10.1038/ng.3399 (opens in a new tab)

27. 27.

    Biegel JA, Busse TM, Weissman BE. SWI/SNF chromatin remodeling complexes and cancer. Am. J. Med. Genet. C Semin. Med. Genet. 2014;166C:350-366.

    Not in our library10.1002/ajmg.c.31410 (opens in a new tab)

28. 28.

    Hoffman GR, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl Acad. Sci. USA. 2014;111:3128-3133.

    Not in our library10.1073/pnas.1316793111 (opens in a new tab)

29. 29.
    Patient derived organoids to model rare prostate cancer phenotypes · 2018

    No notice
30. 30.

    Spahn M, et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer. 2010;127:394-403.

    Not in our library10.1002/ijc.24715 (opens in a new tab)

31. 31.

    Prensner JR, et al. The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. Neoplasia. 2014;16:900-908.

    Not in our library10.1016/j.neo.2014.09.001 (opens in a new tab)

32. 32.

    Coppola V, et al. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene. 2013;32:1843-1853.

    Not in our library10.1038/onc.2012.194 (opens in a new tab)

33. 33.

    Ding Y, et al. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J. Clin. Invest. 2019;129:759-773.

    Not in our library10.1172/jci123557 (opens in a new tab)

34. 34.

    Muthuswami, R. et al. BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer. J. Cell Physiol. 234, 15194–15205 (2019).

    Not in our library10.1002/jcp.28161 (opens in a new tab)

35. 35.

    Hieronymus H, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10:321-330.

    Not in our library10.1016/j.ccr.2006.09.005 (opens in a new tab)

36. 36.

    Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur. Urol. 69, 428–435 (2015).

    Not in our library10.1016/j.eururo.2015.06.046 (opens in a new tab)

37. 37.

    Cancer Genome Atlas Research, N. The molecular taxonomy of primary prostate cancer. Cell. 2015;163:1011-1025.

    Not in our library10.1016/j.cell.2015.10.025 (opens in a new tab)

38. 38.

    Spratt DE, et al. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. J. Clin. Oncol. 2017;35:1991-1998.

    Not in our library10.1200/jco.2016.70.2811 (opens in a new tab)

39. 39.

    Ross AE, et al. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. Eur. Urol. 2016;69:157-165.

    Not in our library10.1016/j.eururo.2015.05.042 (opens in a new tab)

40. 40.

    Chen CD, et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004;10:33-39.

    Not in our library10.1038/nm972 (opens in a new tab)

41. 41.

    Raupach, E. A. et al. Novel functional insights revealed by distinct protein-protein interactions of the residual SWI/SNF complex in SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type. bioRxiv 794776 (2019).

    Not in our library

42. 42.

    Chatterjee SS, Biswas M, Sengupta A. Transcriptional cooperativity between SWI/SNF and nurd chromatin remodelers in acute myeloid leukemia. Exp. Hematol. 2018;64:S58.

    Not in our library10.1016/j.exphem.2018.06.202 (opens in a new tab)

43. 43.

    Yao J, et al. The homeobox gene, HOXB13, regulates a mitotic protein-kinase interaction network in metastatic prostate cancers. Sci. Rep. 2019;9:9715.

    Not in our library10.1038/s41598-019-46064-4 (opens in a new tab)

44. 44.

    Artegiani B, et al. The interaction with HMG20a/b proteins suggests a potential role for beta-dystrobrevin in neuronal differentiation. J. Biol. Chem. 2010;285:24740-24750.

    Not in our library10.1074/jbc.m109.090654 (opens in a new tab)

45. 45.

    Gupta K, Gupta S. Neuroendocrine differentiation in prostate cancer: key epigenetic players. Transl. Cancer Res. 2017;6:S104-s108.

    Not in our library10.21037/tcr.2017.01.20 (opens in a new tab)

46. 46.

    Li Y, et al. SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition. Eur. Urol. 2017;71:68-78.

    Not in our library10.1016/j.eururo.2016.04.028 (opens in a new tab)

47. 47.

    Fraser JA, Sutton JE, Tazayoni S, Bruce I, Poole AV. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen. Sci. Rep. 2019;9:19076.

    Not in our library10.1038/s41598-019-55665-y (opens in a new tab)

48. 48.

    Zhu Y, et al. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate. 2014;74:1086-1094.

    Not in our library10.1002/pros.22819 (opens in a new tab)

49. 49.

    Zhang X, et al. SRRM4 expression and the loss of REST activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer. Clin. Cancer Res. 2015;21:4698-4708.

    Not in our library10.1158/1078-0432.ccr-15-0157 (opens in a new tab)

50. 50.

    Chen R, Li Y, Buttyan R, Dong X. Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells. Oncotarget. 2017;8:84863-84876.

    Not in our library10.18632/oncotarget.19386 (opens in a new tab)

51. 51.

    Chang YT, et al. REST is a crucial regulator for acquiring EMT-like and stemness phenotypes in hormone-refractory prostate cancer. Sci. Rep. 2017;7:42795.

    Not in our library10.1038/srep42795 (opens in a new tab)

52. 52.

    Small, E. J. et al. Neuroendocrine prostate cancer in patients with metastatic castration resistant prostate cancer resistant to abiraterone or enzalutamide: preliminary results from the SU2C/PCF/AACR west coast prostate cancer dream team. In ESMO Vol. 25, iv255-iv279 (Annals of Oncology, 2014).

    Not in our library

53. 53.

    Khalaf DJ, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730-1739.

    Not in our library10.1016/s1470-2045(19)30688-6 (opens in a new tab)

54. 54.

    Zou M, et al. Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discov. 2017;7:736-749.

    Not in our library10.1158/2159-8290.cd-16-1174 (opens in a new tab)

55. 55.

    Zehir A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat. Med. 2017;23:703-713.

    Not in our library10.1038/nm.4333 (opens in a new tab)

56. 56.

    Roy N, et al. Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation. Genes Dev. 2015;29:658-671.

    Not in our library10.1101/gad.256628.114 (opens in a new tab)

57. 57.

    Velcheti V, Wong KK, Saunthararajah Y. EZH2 Inhibitors: take it EZy, it is all about context. Cancer Discov. 2019;9:472-475.

    Not in our library10.1158/2159-8290.cd-19-0090 (opens in a new tab)

58. 58.

    Sun X, et al. Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer. Cancer Cell. 2017;32:574-589.

    Not in our library10.1016/j.ccell.2017.10.007 (opens in a new tab)

59. 59.

    Jones S, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.

    Not in our library10.1126/science.1196333 (opens in a new tab)

60. 60.

    Buscarlet M, et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood. 2014;123:1720-1728.

    Not in our library10.1182/blood-2013-02-483495 (opens in a new tab)

61. 61.

    Wu Q, et al. The BRG1 chromatin remodeling enzyme links cancer cell metabolism and proliferation. Oncotarget. 2016;7:38270-38281.

    Not in our library10.18632/oncotarget.9505 (opens in a new tab)

62. 62.

    Hiramatsu H, et al. The role of the SWI/SNF chromatin remodeling complex in maintaining the stemness of glioma initiating cells. Sci. Rep. 2017;7:889.

    Not in our library10.1038/s41598-017-00982-3 (opens in a new tab)

63. 63.

    Clark J, et al. Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma. Nat. Genet. 1994;7:502-508.

    Not in our library10.1038/ng0894-502 (opens in a new tab)

64. 64.

    Jubierre L, et al. BRG1/SMARCA4 is essential for neuroblastoma cell viability through modulation of cell death and survival pathways. Oncogene. 2016;35:5179-5190.

    Not in our library10.1038/onc.2016.50 (opens in a new tab)

65. 65.

    Laurette, P. et al. Chromatin remodellers Brg1 and Bptf are required for normal gene expression and progression of oncogenic Braf-driven mouse melanoma. Cell Death Differ.27, 29–43 (2019).

    Not in our library10.1038/s41418-019-0333-6 (opens in a new tab)

66. 66.

    Baca SC, Garraway LA. The genomic landscape of prostate cancer. Front. Endocrinol. 2012;3:69.

    Not in our library10.3389/fendo.2012.00069 (opens in a new tab)

67. 67.

    Barbieri CE, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012;44:685-689.

    Not in our library10.1038/ng.2279 (opens in a new tab)

68. 68.

    Armenia J, et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 2018;50:645-651.

    Not in our library10.1038/s41588-018-0078-z (opens in a new tab)

69. 69.

    Link KA, et al. Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res. 2008;68:4551-4558.

    Not in our library10.1158/0008-5472.can-07-6392 (opens in a new tab)

70. 70.

    Jin ML, Kim YW, Jeong KW. BAF53A regulates androgen receptor-mediated gene expression and proliferation in LNCaP cells. Biochem. Biophys. Res. Commun. 2018;505:618-623.

    Not in our library10.1016/j.bbrc.2018.09.149 (opens in a new tab)

71. 71.

    Sandoval GJ, et al. Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. Mol. Cell. 2018;71:554-566.

    Not in our library10.1016/j.molcel.2018.06.040 (opens in a new tab)

72. 72.

    Prensner JR, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 2013;45:1392-1398.

    Not in our library10.1038/ng.2771 (opens in a new tab)

73. 73.

    Raab JR, et al. SWI/SNF remains localized to chromatin in the presence of SCHLAP1. Nat. Genet. 2019;51:26-29.

    Not in our library10.1038/s41588-018-0272-z (opens in a new tab)

74. 74.

    Sun A, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate. 2007;67:203-213.

    Not in our library10.1002/pros.20521 (opens in a new tab)

75. 75.

    Shen H, et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res. 2008;68:10154-10162.

    Not in our library10.1158/0008-5472.can-08-1794 (opens in a new tab)

76. 76.

    Labrecque MP, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J. Clin. Invest. 2019;130:4492-4505.

    Not in our library10.1172/jci128212 (opens in a new tab)

77. 77.

    Lazzaro D, Price M, de Felice M, Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the foetal brain. Development. 1991;113:1093-1104.

    Not in our library10.1242/dev.113.4.1093 (opens in a new tab)

78. 78.

    Sussel L, Marin O, Kimura S, Rubenstein JL. Loss of Nkx2.1 homeobox gene function results in a ventral to dorsal molecular respecification within the basal telencephalon: evidence for a transformation of the pallidum into the striatum. Development. 1999;126:3359-3370.

    Not in our library10.1242/dev.126.15.3359 (opens in a new tab)

79. 79.

    Minocha S, Herr W. Cortical and commissural defects upon HCF-1 loss in Nkx2.1-derived embryonic neurons and glia. Dev. Neurobiol. 2019;79:578-595.

    Not in our library10.1002/dneu.22704 (opens in a new tab)

80. 80.

    Hofer MD, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res. 2004;64:825-829.

    Not in our library10.1158/0008-5472.can-03-2755 (opens in a new tab)

81. 81.

    Norris JD, et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell. 2009;36:405-416.

    Not in our library10.1016/j.molcel.2009.10.020 (opens in a new tab)

82. 82.

    Chen Z, et al. Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13. Proc. Natl Acad. Sci. USA. 2018;115:6810-6815.

    Not in our library10.1073/pnas.1718811115 (opens in a new tab)

83. 83.

    Ewing CM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 2012;366:141-149.

    Not in our library10.1056/nejmoa1110000 (opens in a new tab)

84. 84.

    Abeshouse A, et al. The molecular taxonomy of primary prostate. Cancer Cell. 2015;163:1011-1025.

    Not in our library10.1016/j.cell.2015.10.025 (opens in a new tab)

85. 85.
    CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing · 2016

    No notice
86. 86.

    Cibulskis K, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 2013;31:213.

    Not in our library10.1038/nbt.2514 (opens in a new tab)

87. 87.
    The Ensembl Variant Effect Predictor · 2016

    No notice
88. 88.

    Prandi D, et al. Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol. 2014;15:439.

    Not in our library10.1186/s13059-014-0439-6 (opens in a new tab)

89. 89.

    Beltran H, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Disco. 2011;1:487-495.

    Not in our library10.1158/2159-8290.cd-11-0130 (opens in a new tab)

90. 90.
    The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer · 2014

    No notice
91. 91.

    Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012;29:15-21.

    Not in our library10.1093/bioinformatics/bts635 (opens in a new tab)

92. 92.

    Habegger L, et al. RSEQtools: a modular framework to analyze RNA-Seq data using compact, anonymized data summaries. Bioinformatics. 2010;27:281-283.

    Not in our library10.1093/bioinformatics/btq643 (opens in a new tab)

93. 93.

    Colaprico A, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71.

    Not in our library10.1093/nar/gkv1507 (opens in a new tab)

94. 94.

    Piccolo SR, et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics. 2012;100:337-344.

    Not in our library10.1016/j.ygeno.2012.08.003 (opens in a new tab)

95. 95.

    Dobin A, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.

    Not in our library10.1093/bioinformatics/bts635 (opens in a new tab)

96. 96.

    Nikolayeva O, Robinson MD. edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. Methods Mol. Biol. 2014;1150:45-79.

    Not in our library10.1007/978-1-4939-0512-6_3 (opens in a new tab)

97. 97.

    Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545-15550.

    Not in our library10.1073/pnas.0506580102 (opens in a new tab)

98. 98.

    Liberzon A, et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739-1740.

    Not in our library10.1093/bioinformatics/btr260 (opens in a new tab)

99. 99.

    Rappsilber J, Ishihama Y, Mann M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal. Chem. 2003;75:663-670.

    Not in our library10.1021/ac026117i (opens in a new tab)

100. 100.

     Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods. 2007;4:207-214.

     Not in our library10.1038/nmeth1019 (opens in a new tab)

101. 101.

     Huttlin EL, et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell. 2010;143:1174-1189.

     Not in our library10.1016/j.cell.2010.12.001 (opens in a new tab)

102. 102.

     Tyanova S, et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods. 2016;13:731-740.

     Not in our library10.1038/nmeth.3901 (opens in a new tab)

Cited by papers we hold 3

• Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies · 2023
  No notice
• Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance · 2022
  Corrected
• Loss and revival of androgen receptor signaling in advanced prostate cancer · 2021
  No notice

Questions about this paper

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.